Effects of Preoperative &bgr;-Blocker Use on Clinical Outcomes after Coronary Artery Bypass Grafting: A Report from the Japanese Cardiovascular Surgery Database
暂无分享,去创建一个
H. Miyata | S. Takamoto | K. Fukuda | S. Kohsaka | N. Motomura | S. Kyo | K. Imanaka
[1] Biykem Bozkurt,et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.
[2] L. Fleisher,et al. Perioperative beta blockade in noncardiac surgery: a systematic review for the 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice , 2014, Journal of the American College of Cardiology.
[3] N. Weitzel,et al. Perioperative Medicine , 2021, ASA Monitor.
[4] W. Henderson,et al. Association of perioperative β-blockade with mortality and cardiovascular morbidity following major noncardiac surgery. , 2013, JAMA.
[5] C. O'connor,et al. Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). , 2013, The American journal of cardiology.
[6] Deepak L. Bhatt,et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. , 2012, JAMA.
[7] Janet S. Wright,et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesi , 2011, Journal of the American College of Cardiology.
[8] M. Mack,et al. Preoperative beta-blocker usage: is it really worthy of being a quality indicator? , 2011, The Annals of thoracic surgery.
[9] J. McMurray,et al. Heart failure and chronic obstructive pulmonary disease the quandary of Beta-blockers and Beta-agonists. , 2011, Journal of the American College of Cardiology.
[10] B. Gersh. Lack of Effect of Oral Beta-Blocker Therapy at Discharge on Long-Term Clinical Outcomes of ST-Segment Elevation Acute Myocardial Infarction After Primary Percutaneous Coronary Intervention , 2011 .
[11] Y. Hayashi,et al. Lack of effect of oral beta-blocker therapy at discharge on long-term clinical outcomes of ST-segment elevation acute myocardial infarction after primary percutaneous coronary intervention. , 2010, The American journal of cardiology.
[12] A. Wallace,et al. Association of the Pattern of Use of Perioperative &bgr;-Blockade and Postoperative Mortality , 2010, Anesthesiology.
[13] Volkmar Falk,et al. Guidelines on Myocardial Revascularization the Task Force on Myocardial Revascularization of the European Society of Cardiology (esc) and the European Association for Cardio-thoracic Surgery (eacts) Developed with the Special Contribution of the European Association for Percutaneous Cardiovascular I , 2022 .
[14] Volkmar Falk,et al. Guidelines on myocardial revascularization. , 2010, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[15] William Wijns,et al. Experience with revascularization procedures does matter: low volume means worse outcome. , 2010, European heart journal.
[16] P. Fitzgerald,et al. SPIRIT III JAPAN versus SPIRIT III USA: a comparative intravascular ultrasound analysis of the everolimus-eluting stent. , 2010, The American journal of cardiology.
[17] Takeshi Kimura,et al. Difference in patient profiles and outcomes in Japanese versus American patients undergoing coronary revascularization (collaborative study by CREDO-Kyoto and the Texas Heart Institute Research Database). , 2010, The American journal of cardiology.
[18] R. Nagai,et al. Beta-blocker prescription among Japanese cardiologists and its effect on various outcomes. , 2010, Circulation journal : official journal of the Japanese Circulation Society.
[19] H. Miyata,et al. First report on 30-day and operative mortality in risk model of isolated coronary artery bypass grafting in Japan. , 2008, The Annals of thoracic surgery.
[20] Denis Xavier,et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial , 2008, The Lancet.
[21] Teruhisa Kazui,et al. Thoracic and cardiovascular surgery in Japan during 2004. , 2006, The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi.
[22] Teruhisa Kazui,et al. Thoracic and cardiovascular surgery in Japan during 2004. , 2006, The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi.
[23] R. Collins,et al. Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial , 2005, The Lancet.
[24] G. Guyatt,et al. Are the recommendations to use perioperative β-blocker therapy in patients undergoing noncardiac surgery based on reliable evidence? , 2004, Canadian Medical Association Journal.
[25] H. Ogawa,et al. Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. , 2003, The American journal of cardiology.
[26] E. Peterson,et al. Preoperative beta-blocker use and mortality and morbidity following CABG surgery in North America. , 2002, JAMA.
[27] A. Wood. Racial differences in the response to drugs--pointers to genetic differences. , 2001, The New England journal of medicine.
[28] Jeroen J. Bax,et al. Predictors of Cardiac Events After Major Vascular Surgery Role of Clinical Characteristics, Dobutamine Echocardiography, and b-Blocker Therapy , 2001 .
[29] R. Mongiardo,et al. Major racial differences in coronary constrictor response between japanese and caucasians with recent myocardial infarction. , 2000, Circulation.
[30] A. Maseri,et al. Racial heterogeneity in coronary artery vasomotor reactivity: differences between Japanese and Caucasian patients. , 1999, Journal of the American College of Cardiology.
[31] Effect of metoprolol on death and cardiac events during a 2-year period after coronary artery bypass grafting. The MACB Study Group. , 1995, European heart journal.
[32] B. Psaty,et al. The Relative Risk of Incident Coronary Heart Disease Associated with Recently Stopping the Use of ??-Blockers , 1991 .
[33] B. Psaty,et al. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. , 1990, JAMA.
[34] G R Wilkinson,et al. Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. , 1989, The New England journal of medicine.
[35] S. Nattel,et al. Prevention of propranolol withdrawal mechanism by prolonged small dose propranolol schedule. , 1982, The American journal of cardiology.
[36] L Goldman,et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. , 1977, The New England journal of medicine.
[37] Jacob Cohen. The t Test for Means , 1977 .
[38] R. Miller,et al. Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy. , 1975, The New England journal of medicine.